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Abstract
Objective—To examine the uptake of ART among pregnant women referred to an ART service
and the associated rates and risk factors for vertical HIV transmission.
Method—Retrospective analysis of an observational cohort at a community ART clinic in Cape
Town.
Results—Between 2002 and 2008, 367 treatment-naïve pregnant women accessed the clinic. The
median age was 27.5 years, and median gestation at presentation was 28 weeks. The median
baseline CD4 count and viral load were 134 cells/µl and 28 282 copies/ml. Two hundred and
sixty-five women (72%) commenced ART before giving birth, 73 women (20%) were referred for
prevention of mother-to-child transmission therapy (PMTCT), and 29 (8%) received no
intervention. Among ART-eligible women, 13% were lost to follow-up. Of those starting ART,
median duration of therapy prior to birth was 7.6 weeks (interquartile range (IQR) 4 – 11.9). The
HIV transmission rate was 5.1% (95% confidence interval (CI) 2.8 – 9.0%). Factors associated
with transmission were advanced maternal WHO disease stage (odds ratio (OR) 9.57, p=0.02), and
follow-up viral load above 50 copies/ml (OR 3.64, p=0.03). Each additional week on ART
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reduced transmission by 20% (p=0.05). There was no HIV transmission among women who
received more than 8 weeks’ therapy.
Conclusions—The rate of HIV transmission in this study was higher than reported in high-
income countries. Prevention of vertical transmission with ART was hindered by women
presenting late in pregnancy and with advanced stage of HIV disease. Interventions that facilitate
earlier ART commencement and improve programmatic retention of pregnant women are
required.
The South African national HIV prevalence among antenatal women aged 15 – 49 years in
the 2008 antenatal care (ANC) survey was 29.3% (95% confidence interval (CI) 28.5 –
30.1%), and 16.1% (CI 12.6 – 20.2%) in the Western Cape, which is the least burdened
province.1 From 2006 to 2007, 67.5% of HIV-positive women in the Western Cape received
at least a single dose of nevirapine during labour.2
All HIV-positive pregnant women who meet South African national treatment guidelines
may be referred to antiretroviral treatment clinics for antiretroviral therapy (ART) as per
World Health Organization (WHO) guidelines.3 South Africa follows 2002 WHO guidelines
with stage IV disease or a CD4 cell count of 200 cells/µl as a threshold for starting ART.
Perinatal transmission risk increases with low CD4 counts and high viral loads in the
mother.4–6 Large cohort studies in the developed world have shown ART to be superior to
AZT monotherapy,7,8 and the WHO recommends that all pregnant women with stage III or
IV disease, or a CD4 cell count <350 cells/µl, should receive ART.9,10 While HIV
transmission rates range from 0 – 2.9% for women in the developed world,7,8,11–13 the
efficacy of ART in preventing vertical transmission has not been clearly documented in
resource-limited settings. A study of 326 women in Côte d’Ivoire showed improved
prevention of ART v. prevention of mother-to-child transmission therapy (PMTCT) (2.3%
v. 16.1%, p<0.0001; where PMTCT was either AZT from 36 weeks or AZT and lamivudine
from 32 weeks, with intrapartum nevirapine and 1 week’s AZT for the infant).14
Transmission rates from a hospital-based combined antenatal and antiretroviral clinic in
Johannesburg were 5% for 689 patients on ART.15 Since these data come from small
research cohorts, more programmatic data on ART initiation in pregnancy are needed.
We studied the uptake of ART and rates and risk factors for vertical HIV transmission
among pregnant women referred for ART at a large community ART clinic, and the
characteristics of mothers receiving ART compared with PMTCT or no intervention.
Methods
The ART service was based at the Gugulethu Community Health Centre in Nyanga, Cape
Town.16 This peri-urban area is home to a predominantly black population of over 300 000,
most of whom live in low socio-economic conditions. In 2005, the antenatal HIV
seroprevalence was 29%.17 By September 2008, 3 407 patients had been started on ART at
this clinic according to national guidelines, except that the commencement CD4 cell count
threshold was extended from <200 cells/µl to <250 cells/µl for pregnant women in January
2006. Pregnant women were referred for ART from an onsite ANC service 130 m away.18
The ART service has regular laboratory monitoring and adherence support from community-
based peer counsellors.16 Enrolment of pregnant patients was stratified by gestational age so
that women <24 weeks pregnant would follow the standard protocol of ART
commencement within 4 weeks; women between 24 and 34 weeks were fast-tracked to
initiate therapy in 2 weeks; and those >34 weeks pregnant were aimed to start within a week.
Drugs for fast-tracked patients were ordered on the day of their first attendance, and they
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were escorted to meet the counsellor team leader by their doctor. They could commence
treatment even if they had not yet attended all 3 education sessions, although these had to be
attended in due course.
Patients referred after 28 weeks were started on AZT monotherapy at the ANC service while
awaiting ART. Zidovudine, lamivudine and nevirapine was the regimen of choice for
pregnant women unless contraindicated, in which case an alternative regimen was
constructed. ART-naïve women accessing the service between 1 September 2002 and 1
March 2008 were eligible for analysis if they were pregnant at first attendance. Singleton
and multiple pregnancies were evaluable.
Women started on triple therapy before birth were categorised as the ‘ART’ group; women
referred back to a maternity outpatient unit for PMTCT and not commenced on ART were
categorised as the ‘PMTCT’ group; and women not started on ART prior to birth with no
documented referral for PMTCT or having received AZT prior to birth were categorised as
the ‘No intervention’ group.
Demographic data, WHO staging, treatment outcomes, laboratory results, ART regimens
and regimen changes were recorded in a prospectively maintained database for all patients
referred to the ART service since the start of the clinic in September 2002. Infant HIV status
and age at polymerase chain reaction (PCR) testing were verified using the regional
laboratory PCR test database. National guidelines are that PCR testing should take place at 6
weeks of age.3 Infant HIV status was followed up until September 2008.
Data analysis was by STATA/IC version 10. Fisher’s exact tests and Wilcoxon rank-sum
tests were used to compare proportions and medians, respectively. Multiple logistic
regression was used to examine the odds of vertical transmission according to maternal
clinical characteristics. The upper bound of the rate of transmission was calculated
according to Ghent working group formulae.19 For calculating the upper bound, only first-
born twins were included as per the formula. For other calculations, both twins were
included. All women provided informed consent. Data collection from this clinic for the
study was approved by the University of Cape Town Research Ethics Committee.
Results
Maternal characteristics
Between 2002 and 2008, 2 350 ART-naïve women were referred for ART, and 367 were
identified as pregnant at first clinic attendance. Their median age was 27.5 years (range 15 –
44); median gestational age 28 weeks (interquartile range (IQR) 24 – 32), and the median
baseline CD4 cell count and viral load were 134/µl (IQR 88 – 179) and 28 282 copies/ml
(IQR 8 103 – 74 859) respectively.
Intervention received
Two hundred and sixty-five mothers (73%) started ART prior to giving birth; 73 (20%) were
referred back from the ART clinic to the midwife obstetric unit (MOU) for PMTCT, and 29
(8%) had no intervention (Fig. 1). After exclusion of 6 women who were confirmed to be
ineligible for ART, 13 refused ART and 7 started ART later. Altogether, 44 out of 346
(12.7%, 95% CI 9.6 – 16.7%) eligible women were lost to follow-up or refused ART and
therefore were not started on ART.
Women who commenced ART started a median of 21 days after enrolment (IQR 14 – 29);
the median period on ART before birth was 7.6 weeks (IQR 4 – 11.9) (Fig. 2). The choice of
ART regimen depended on maternal condition. Two hundred and forty-six (93%) started
Fitzgerald et al. Page 3
S Afr Med J. Author manuscript; available in PMC 2014 March 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
AZT, 3TC and NVP; 12 (5%) commenced d4T, 3TC and NVP owing to anaemia; 6 (2%)
started d4T 3TC and EFV owing to TB and advanced pregnancy; and 1 (0.3%) started d4T
3TC and Kaletra. There were 8 regimen changes during pregnancy.
Comparison of PMTCT, ART and No Intervention Received
The demographics and outcomes of the groups of ART and PMTCT were compared (Table
I). The PMTCT group were more advanced in their pregnancy, and had higher baseline CD4
cell counts and lower baseline viral loads (p<0.001, p<0.001, p=0.013 respectively). There
was no difference in distribution of live births and stillbirths, or in HIV status of infants. The
groups that received no intervention were significantly younger than those started on ART
(p=0.02), and were more likely to have TB (p=0.015) and to have stillbirths (p=0.004). Both
groups gave birth at earlier gestational age than the ART group.
Maternal and pregnancy outcomes
Of the women commenced on ART, 16 (6%) were lost to the programme prior to giving
birth. Of these, 9 (3%) were lost to followup, 5 (2%) died and 2 were transferred to another
ART clinic. Of the 5 deaths, 3 were due to TB and 1 to pneumonia, and the cause of the fifth
was unknown. Overall, 34 (9.3%) pregnant women had TB.
There were 376 pregnancies among the 367 women including 9 sets of twins. There were
279 live births (74%), 21 stillbirths/miscarriages (6%), 4 terminations (1%) and 72 (19%)
were of unknown outcome. Median estimated gestational age at birth or stillbirth was 38
weeks (IQR 36 – 40). There were 232 HIV-negative infants (83%), 11 HIV-positive (4%),
and 36 (13%) infants of unknown HIV status. Median infant age at PCR was 13 weeks (IQR
10 – 17).
Twenty-one (5.6%) pregnancies ended in either stillbirth or miscarriage, 2 at 19 weeks’
gestation, 18 between 28 and 42 weeks, and 1 unrecorded. Stillbirths and miscarriages were
analysed together. In multivariate analysis, longer duration of pregnancy at enrolment (OR
0.88, p=0.001) and commencing ART v. no intervention (OR 0.1, p=0.007) were protective.
Higher baseline log viral load increased the risk (OR 2.46, p=0.07).
Nine infants died within 1 year of birth; the median age at death was 14 weeks (IQR 6 – 26).
Three were HIV-positive, 2 negative and 4 unknown. Maternal TB was associated with
infant death in crude analysis (p=0.042) but, in multivariate analysis, only HIV-positive
status was independently associated with infant death (OR 30.5, p=0.001).
Risk factors for vertical transmission
The groups of HIV-negative, positive and status-unknown infants born to women
commenced on ART were compared (Table II). There were 241 births in this group. Median
age at PCR was 13 weeks (IQR 10 – 17). Two hundred and six infants were negative (85%),
11 (4.6%) positive, and 24 (10%) of unknown status (Fig. 1). Four of the infants of unknown
HIV status died under the age of 17 weeks, and the remaining mothers of 20 infants had
been transferred to another clinic, were lost to follow-up, or the infant had not been tested.
The mother of infants of unknown status were younger (p=0.018).
After exclusion of unknowns, the transmission rate was 5.1% (95% CI 2.8 – 9.0%). The
upper bound for the rate of transmission within the ART group estimated by the Ghent
working group formulae was 7.83% (95% CI 4.9 – 12.2).19
Crude analysis showed duration of ART before birth to be significantly associated with
transmission (p=0.029). All of the mothers who gave birth to HIV-positive infants had less
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than 8 weeks’ ART prior to delivery. Advanced maternal disease stage (stage III or IV
compared with I or II, p=0.01), gestation at enrolment (p=0.036) and first follow-up viral
load >50 copies/ml (p=0.018) were also significantly associated. No significant difference
was found in HIV status of infant according to maternal ART regimen.
Multivariate analysis of the HIV-positive versus negative infants revealed duration of ART
to be an independent predictor of transmission (Table III). Each week reduced risk of
transmission by 20% (p=0.005). Additional independent predictor variables were maternal
WHO stage at enrolment and viral load at first follow-up. Women with WHO stage 3 or 4
disease were 9.5 times more likely to transmit (p=0.02) than those at stage 1. Those with
incompletely suppressed virus (viral load >50 copies/ml) at 16 weeks on ART had a
transmission rate of 10% (95% CI 4 – 20%), whereas those with a viral load of <50 copies/
ml had a transmission rate of 3% (95% CI 1 – 8%).
Discussion
The HIV transmission rate of those starting HAART during pregnancy was 5.1%, with an
upper bound of 7.8% that was higher than rates reported in the developed world.7,8,11 Our
study demonstrated that shorter duration of HAART in pregnancy was strongly associated
with increased HIV transmission. The major factor limiting the potential duration of ART
was advanced gestation at the time of presentation to the antenatal services. The period of
ART was further shortened by systems delays in referral from the antenatal to the ART
service severely restricting the time available to prepare women for ART.
The median gestational age at enrolment was 28 weeks. However, 25% of patients presented
after 31 weeks of pregnancy. The potential duration of ART was further restricted because
delivery tended to occur early at a median of 38 weeks with 25% of mothers giving birth
before 36 weeks’ gestation. This limited window of opportunity for ART initiation resulted
in a strategy of fast-tracking of women presenting in the third trimester of pregnancy. Fast-
tracking may not be an optimal strategy but was considered necessary as an emergency
intervention precipitated by late booking. Women accessing ART programmes during
pregnancy are significantly more likely to be lost to follow-up than their non-pregnant
peers.20,21 The reasons behind poor retention of pregnant women within ART programmes
are uncertain; however, too little preparation prior to ART initiation could be a contributing
factor.
Lack of treatment readiness was also an important constraint to implementation as 21% of
eligible women either refused or delayed commencement of ART to after delivery. Such
women had already successfully navigated their way through antenatal booking and referral
before attending the ART clinic. As losses may occur at earlier stages of the entire cascade
of antenatal clinic attendance, counselling and testing, referral for treatment, initiation of
HAART and ongoing adherence to protocol, true losses from the programme are likely to
have been even greater.
In the developed world, vertical HIV transmission rates of between 0% and 2.9% have been
achieved for women on HAART.8,11–13 Triple therapy (HAART) is superior to AZT
monotherapy in preventing mother-to-child transmission.7,8 Similarly, in this study, there
were no HIV transmissions among women who received at least 8 weeks of therapy before
delivery. The overall HIV transmission rate among our patients highlights that the
effectiveness of HAART for vertical transmission is affected by the potency of the regimen
used and also by other operational constraints. One contributing factor is that the present
national ART treatment guidelines restrict HAART to those with AIDS or CD4 <200 cells/
Fitzgerald et al. Page 5
S Afr Med J. Author manuscript; available in PMC 2014 March 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
µl. Pregnant black women with high viral loads require several weeks of therapy to
completely suppress viral load.12
Our data highlight that the effectiveness of HAART will be greatly increased if women can
be encouraged to access antenatal services at an earlier stage of gestation. Antenatal services
should also place emphasis on retaining women within care.
There were few adverse events related to use of HAART but there were multiple sequelae of
untreated HIV. However, a significant proportion of women refused or delayed initiation of
HAART. Social marketing of the benefits of HAART is urgently required to overcome the
negative messages previously propagated by South Africa’s health authorities. The limited
window of opportunity for initiating HAART in women presenting later in pregnancy has
required fast-tracking them. Whether inadequate preparation due to fast-tracking plays a part
in the poor retention of pregnant women in HAART programmes must be investigated.
We studied the effectiveness of HAART and did not address important parameters such as
mode of delivery, breastfeeding and infant post-exposure prophylaxis. Additionally,
pregnancy outcomes of the women referred back for PMTCT were unknown. Direct
comparison of the effectiveness of PMTCT v. HAART in this study was therefore not
possible. Interpreting the analysis of live v. stillbirths is complex, as women having
miscarriages or early stillbirths would not attend the antenatal clinic, which builds in an
ascertainment bias. Similarly, longer duration of pregnancy at enrolment emerged as
protective, but this may have been because the more advanced the pregnancy, the less time
there is for a stillbirth to occur.
The generalisability of the data to other parts of South Africa and the rest of sub-Saharan
Africa is difficult to establish. This is one unique programme, and other public sector
services may initiate ART more slowly. In other areas, antenatal booking may be later still,
and treatment initiation may be further slowed by delays in CD4 enumeration. Further
programmatic data are needed.
Summary
The rate of vertical HIV transmission (5.1%) among women commencing ART in this
cohort was higher than that reported in the developed world, and was associated with
advanced immunodeficiency at presentation and late initiation of HAART. No HIV
transmissions occurred among women who received more than 8 weeks of HAART.
However, 12.7% of women eligible for ART during pregnancy did not receive it and, in
those starting HAART, the median length of therapy before delivery was less than 8 weeks.
The effectiveness of HAART will be improved by earlier presentation to antenatal services
and subsequent retention in care. Increased uptake of HAART will require social marketing
of the considerable benefits of HAART in this patient population.
Acknowledgments
LGB, LM and RW were funded in part by the National Institutes of Health (NIH) through a CIPRA grant
1U19AI53217-01 and RW by an RO1 grant (A1058736-01A1). SDL was funded by the Wellcome Trust, London,
UK. The authors gratefully acknowledge the dedicated staff of the Hannan Crusaid ART clinic, the Desmond Tutu
HIV Centre, and Di Hardy for access to the NHLS database.
References
1. UNAIDS. [accessed 14 October 2008] Progress Report on Declaration of Commitment on HIV and
AIDS. Republic of South Africa. Reporting Period: January 2006 – December 2007. http://
data.unaids.org/pub/Report/2008/south_africa_2008_country_progress_report_en.pdf
Fitzgerald et al. Page 6
S Afr Med J. Author manuscript; available in PMC 2014 March 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
2. Health Systems Trust. [accessed 5 November 2008] The District Health Barometer – Year 2006/07.
http://www.hst.org.za/publications/717
3. Policy and Guidelines for the Implementation of the PMTCT Programme. Pretoria: National
Department of Health; http://www.doh.gov.za/docs/policy/pmtct-f.html [accessed 10 October 2008]
4. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of Human
Immunodeficiency Virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials
Group Study 185 team. N Engl J Med. 1999; 341(6):385–393. [PubMed: 10432323]
5. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1
RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl
J Med. 1999; 341(6):394–402. [PubMed: 10432324]
6. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet.
1992; 339(8800):1007–1012. [PubMed: 1349050]
7. Cooper ER, Charurat M, Mofenson LM, et al. Combination antiretroviral strategies for the treatment
of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir
Immune Defic Sydnr. 2002; 29:484–494.
8. Shapiro, D.; Tuomala, R.; Pollack, H., et al. Mother-to-child HIV transmission risk according to
antiretroviral therapy, mode of delivery, and viral load in 2895 U.S. women (PACTG 367). 11th
Conference on Retroviruses and Opportunistic Infections; February 2004; San Francisco, CA.
[Abstract 99].
9. World Health Organization. [accessed 10 October 2008] Antiretroviral Therapy for HIV Infection in
Adults and Adolescents: Recommendations for a Public Health Approach. 2006 revision. http://
www.who.int/hiv/pub/guidelines/WHO%20Adult%20ART%20Guidelines.pdf
10. World Health Organization. [accessed 30 November 2009] Rapid Advice: Use of Antiretroviral
Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants. http://www.who.int/
hiv/pub/mtct/rapid_advice_mtct.pdf
11. Townsend CL, Cortina-Borja M, Peckham CS, de Ruiter A, Lyall H, Tookey PA. Low rates of
mother-to-child transmission of HIV following effective pregnancy interventions in the United
Kingdom and Ireland: 2000–2006. AIDS. 2008; 22(8):973–981. [PubMed: 18453857]
12. Patel D, Cortina-Borja M, Thorne C, Newell ML. European Collaborative Study. Time to
undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected
pregnant women. Clin Infect Dis. 2007; 44(12):1647–1656. [PubMed: 17516411]
13. Warszawski J, Tubiana R, Le Chenadec J, et al. ANRS French Perinatal Cohort. Mother-to-child
HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS.
2008; 22(2):289–299. [PubMed: 18097232]
14. Ekouevi DK, Coffie PA, Becquet R, et al. Antiretroviral therapy in pregnant women with advanced
HIV disease and pregnancy outcomes in Abidjan, Cote d’Ivoire. AIDS. 2008; 22(14):1815–1820.
[PubMed: 18753864]
15. Black V, Hoffman RM, Sugar CA, et al. Safety and efficacy of initiating highly active
antiretroviral therapy in an integrated antenatal and HIV clinic in Johannesburg, South Africa. J
Acquir Immune Defic Syndr. 2008; 3:276–281. [PubMed: 18845949]
16. Bekker LG, Myer L, Orrell C, Lawn S, Wood R. Rapid scale-up of a community-based HIV
treatment service: programme performance over 3 consecutive years in Guguletu, South Africa. S
Afr Med J. 2006; 96(4):315–320. [PubMed: 16670804]
17. South African Government Information. [accessed 31 October 2008] HIV & AIDS and STI
strategic plan for South Africa 2007–2011. http://www.info.gov.za/otherdocs/2007/aidsplan2007/
executive_summary.pdf
18. Stinson K, Boulle A, Coetzee D, Abrams E, Myer L. Initiation of highly active antiretroviral
therapy among pregnant women in Cape Town, South Africa. Trop Med Int Health. In press.
19. Newell ML, Coovadia H, Cortina-Borja M, et al. Lancet. 2004; 364(9441):1236–1243. [PubMed:
15464184]
20. Kaplan R, Orrell C, Zwane E, Bekker LG, Wood R. Loss to follow-up and mortality among
pregnant women referred to a community clinic for antiretroviral treatment. AIDS. 2008; 22(13):
1679–1681. [PubMed: 18670232]
Fitzgerald et al. Page 7
S Afr Med J. Author manuscript; available in PMC 2014 March 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
21. Karcher H, Omondi A, Odera J, Kunz A, Harms G. Risk factors for treatment denial and loss to
followup in an antiretroviral treatment cohort in Kenya. Trop Med Int Health. 2007; 12(5):687–
694. [PubMed: 17445136]
Fitzgerald et al. Page 8
S Afr Med J. Author manuscript; available in PMC 2014 March 14.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 1.
Flowchart of interventions received by pregnant women accessing ART clinic, and infant
outcomes of those commencing ART.
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Fig. 2.
Timeline of ART initiation in women commencing therapy from conception until first
follow-up viral load test after delivery using median values of days.
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Table III
Risk factors associated with vertical HIV transmission
Odds
ratio
95%
confidence
interval p-value
Stage 1 v. stage 2 1.32 0.1 18.25 0.84
Stage 1 v. stage 3 and 4 9.68 1.47 63.62 0.02
Age at enrolment 0.85 0.71 1.02 0.08
Weeks on ART prior to birth 0.8 0.64 0.1 0.05
Follow-up viral load <50 v. >50 5.78 1.17 28.51 0.031
Follow-up CD4 1 0.1 1.01 0.243
Log baseline viral load 0.73 0.24 2.23 0.57
Baseline CD4 1 0.99 1.02 0.86
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